Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics
- PMID: 39000461
- PMCID: PMC11242320
- DOI: 10.3390/ijms25137354
Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics
Abstract
Antigen presentation is a crucial mechanism that drives the T cell-mediated immune response and the development of Multiple Sclerosis (MS). Genetic alterations within the highly variable Major Histocompatibility Complex Class II (MHC II) have been proven to result in significant changes in the molecular basis of antigen presentation and the clinical course of patients with both Adult-Onset MS (AOMS) and Pediatric-Onset MS (POMS). Among the numerous polymorphisms of the Human Leucocyte Antigens (HLA), within MHC II complex, HLA-DRB1*15:01 has been labeled, in Caucasian ethnic groups, as a high-risk allele for MS due to the ability of its structure to increase affinity to Myelin Basic Protein (MBP) epitopes. This characteristic, among others, in the context of the trimolecular complex or immunological synapsis, provides the foundation for autoimmunity triggered by environmental or endogenous factors. As with all professional antigen presenting cells, macrophages are characterized by the expression of MHC II and are often implicated in the formation of MS lesions. Increased presence of M1 macrophages in MS patients has been associated both with progression and onset of the disease, each involving separate but similar mechanisms. In this critical narrative review, we focus on macrophages, discussing how HLA genetic alterations can promote dysregulation of this population's homeostasis in the periphery and the Central Nervous System (CNS). We also explore the potential interconnection in observed pathological macrophage mechanisms and the function of the diverse structure of HLA alleles in neurodegenerative CNS, seen in MS, by comparing available clinical with molecular data through the prism of HLA-immunogenetics. Finally, we discuss available and experimental pharmacological approaches for MS targeting the trimolecular complex that are based on cell phenotype modulation and HLA genotype involvement and try to reveal fertile ground for the potential development of novel drugs.
Keywords: HLA; HLA-immunogenetics; T cells; immune response; macrophages; microglia; multiple sclerosis.
Conflict of interest statement
We declare that there are no conflicts of interest regarding the publication of this manuscript.
Figures
Similar articles
-
T cell receptor V genes in multiple sclerosis: increased use of TCRAV8 and TCRBV5 in MBP-specific clones.Int Rev Immunol. 1999;18(1-2):9-36. doi: 10.3109/08830189909043017. Int Rev Immunol. 1999. PMID: 10614737 Review.
-
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).J Neuroinflammation. 2012 Feb 8;9:29. doi: 10.1186/1742-2094-9-29. J Neuroinflammation. 2012. PMID: 22316121 Free PMC article.
-
Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium.Hum Mol Genet. 2007 Aug 15;16(16):1951-8. doi: 10.1093/hmg/ddm142. Epub 2007 Jun 20. Hum Mol Genet. 2007. PMID: 17584771
-
Human leucocyte antigen (HLA) class I and II typing in Belgian multiple sclerosis patients.Acta Neurol Belg. 2017 Mar;117(1):61-65. doi: 10.1007/s13760-016-0716-0. Epub 2016 Oct 28. Acta Neurol Belg. 2017. PMID: 27797002
-
The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis.Dis Markers. 2019 Nov 6;2019:1409069. doi: 10.1155/2019/1409069. eCollection 2019. Dis Markers. 2019. PMID: 31781296 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous